Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
Wednesday, July 26, 2023IntelGenx Corp TSXIGXOTCQBIGXT the Company or IntelGenx today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a plan...
ARTIBIO and SpectronRx Enter Partnership Agreement to Manufacture Key Components of ARTIBIO's AlphaDirect™ Technology
Tuesday, July 25, 2023ARTBIO Inc a clinicalstage radiopharmaceutical company developing a new class of alpha radioligand ART targeted therapies and SpectronRx a leading radiopharmaceutical developer and manufacturer today announced a global strategic partnership
MitoSense Officially Joins CAMP as Partner for Advanced Therapy Medicinal Products (ATMPs) Development
Tuesday, July 25, 2023MitoSense and the Centre for Advanced Medical Products CAMP are delighted to announce that MitoSense has officially joined CAMP as a partner for the development of advanced therapy medicinal products ATMPs
ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates
Monday, July 24, 2023ImmunoBiochem Corporation a privatelyheld biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics announced today a multitarget license and option agreement with ImmunoGen Inc Nasdaq...
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Monday, July 24, 2023Curium a world leader in nuclear medicine announced today the publication of the results of its European multicenter prospective crossover clinical trial which compared F piflufolastat FDCFPyL versus Ffuoromethylcholine PETCT in patients with first b...
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
Friday, July 21, 2023Altamira Therapeutics Ltd Altamira or the Company Nasdaq CYTO a company dedicated to developing therapeutics that address important unmet medical needs announced today that it has entered into an exclusive agreement with Pharma Nordic AS for the mark...
Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients
Friday, July 21, 2023Comera Life Sciences Holdings Inc Nasdaq CMRA Comera or the Company a life sciences company developing a new generation of biologic medicines to improve patient access safety and convenience today announced a partnership with Quality Chemical Laborat...
GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
Friday, July 21, 2023LimmaTech Biologics AG LimmaTech Bio a clinicalstage biotech company developing vaccines for the prevention of lifethreatening diseases signed an inlicense agreement with GlaxoSmithKline Biologicals SA LSENYSE GSK enabling LimmaTech Bio to further de...
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
Thursday, July 20, 2023MeiraGTx Holdings plc Nasdaq MGTX a vertically integrated clinical stage gene therapy company today announced that after a successful inspection by the Irish Health Products Regulatory Authority HPRA it has received a Commercial ManufacturersImporter...
Riparian Pharmaceuticals Announces Agreements with Pfizer for Novel Cardiovascular Programs
Thursday, July 20, 2023Riparian Pharmaceuticals a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases today announced it has entered into an exclusive license agreement and research agreement with Pfizer
